Regulation of protein abundance in normal human tissues

Competing Interest Statement

MPS is a cofounder and scientific advisor of Crosshair Therapeutics, Exposomics, Filtricine, Fodsel, iollo, InVu Health, January AI, Marble Therapeutics, Mirvie, Next Thought AI, Orange Street Ventures, Personalis, Protos Biologics, Qbio, RTHM, SensOmics. MPS is a scientific advisor of Abbratech, Applied Cognition, Enovone, Jupiter Therapeutics, M3 Helium, Mitrix, Neuvivo, Onza, Sigil Biosciences, TranscribeGlass, WndrHLTH, Yuvan Research. MPS is a cofounder of NiMo Therapeutics. MPS is an investor and scientific advisor of R42 and Swaza. MPS is an investor in Repair Biotechnologies. AIN receives royalties from the University of Michigan for the sale of MSFragger software licenses to commercial entities. All license transactions are managed by the University of Michigan Innovation Partnerships office, and all proceeds are subject to university technology transfer policy. TL is an adviser and has equity at Variant Bio, and has received speaker honoraria from AbbVie.

Funding Statement

This work was supported R35GM127063 (H.T., H.F.), R01HL142017 (H.T, A.P.R) and U01HL131042 (M.P.S., H.T., H.F., L.J., R.J., J.C.). The Genotype-Tissue Expression (GTEx) project was supported by the Common Fund of the Office of the Director of the NIH, with additional funds provided by the NCI, NHGRI, NHLBI, NIDA, NIMH and NINDS. The enhanced Genotype-Tissue Expression (eGTEx) consortium was supported by NIH grants U01MH104393, U01HG007598, U01HG007599, U01HG007593, U01HG007591, U01HG007610, U01HG007601 and U01HG007611.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

“Under the law, deceased individuals are not considered to be human subjects and do not require consent for research; however, GTEx management decided to require authorization due to the large amount of sequencing data to be produced and made publically available.” (Carithers LJ, Ardlie K, Barcus M, et al. A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project. Biopreserv Biobank. 2015;13(5):311-319.) The samples used in our study were de-identified before we obtained them.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes